The economic impact of the HIV epidemic in the United States. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The economic impact of the HIV epidemic in the United States.

AIDS Updates; 4(5):1-12 1991. Unique Identifier : AIDSLINE ICDB/93686724
Scitovsky AA; Palo Alto Medical Foundation, Res. Inst., Palo Alto, CA

Abstract: This article gives a brief survey of the demographics of AIDS incidence in the United States, from the first reports by the Centers for Disease Control in mid-1981 through February 1991, and a discussion of the direct medical care costs of the HIV epidemic (costs). These topics are addressed: costs of persons with AIDS (PWAs; lifetime costs of PWAs, national costs of AIDS and impact of AIDS on public hospitals); costs of HIV-infected persons (HIVIPs) other than PWAs, financing medical care of HIV-infected persons (PWAs, HIVIPs other than PWAs and AZT); other HIV-related costs (eg, nonpersonal direct costs, such as blood screening to assure safety of the blood supply, special infection control measures to protect health care personnel and other patients against HIV, research and education); estimates of the indirect costs of the HIV epidemic (value of lost output due to morbidity and mortality); and prospects for the future. (40 Refs)
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY/ECONOMICS/ *EPIDEMIOLOGY/PREVENTION & CONTROL Demography Financing, Government *Health Care Costs Health Education Hospitals Human Zidovudine/THERAPEUTIC USE JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/drugtherapy/economics/KWDepidemiology/prevention&controldemographyfinancing,governmentKWDhealthcarecostshealtheducationhospitalshumanzidovudine/therapeuticusejournalarticle
930228
M9320877

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .